Comments
Drugmaker Sun Pharmaceutical Industries has acquired Boston-based Pharmalucence Inc for an undisclosed sum. The latter has a sterile injectables facility and research capabilities in the US.
Sun Pharma’s latest acquisition comes within months of its $4 billion proposal (in April) to acquire troubled drug company Ranbaxy. That transaction is awaiting regulatory and other approvals.
Sun’s acquisition of Pharmalucence will help strengthen its presence in the sterile injectables segment, since the manufacturing unit is close to the market, said Ranjit Kapadia, Senior Vice-President of Centrum Broking.
Pharmalucence has around 100 professionals, he said, and regulatory approvals for its new facility are expected to come through this year.
On Wednesday, Sun Pharma shares closed marginally higher, at ₹743, on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.